Vistara’s TRIFECTA strategy is at the intersection of the innate degradation mechanism of the clinical target, the molecules which alter its degradation, and solutions which can be created for clinical applications.

We use proteomics to observe the proteostasis mechanisms of the clinical candidate in the sample.

Then we design solutions for targeted disruption of the candidate using insights gained from holistic views of the ubiquitome, crosstalk with biological pathways, and small molecule discovery.  
Our next-gen tools help drug discovery research in Oncology, Inflammation, and Neurodegenerative diseases.


Our database of E3 ligases, motifs, scaffolding proteins, and their cell type specificities guide the selection of candidates for targeted degradation.


With speed, precision, iteration and ubiquitome-wide compound screening processes we select the best combinations of sample, target, and TPD candidate. 


We are expanding the knowledgebase of E3 ligase degrome signatures and crosstalk with other pathways for modeling biological decision-making.


Our bioactive peptides target proteins intracellularly via polyubiquitination or other mechanisms! We engineer cells with the peptides as a tool for drug discovery.

   Our ‘outside-in’ process for getting from Sample to Solution!

By eliminating redundant information and navigating to the problem, we arrive at a definitive set of sample-specific criteria for designing solutions for targeted disruption of the candidate protein (TPD)

‘What’s in the sample?’

‘What are the plausible solutions based on data from the sample?’

‘How can we apply our tools for navigating the problem ?’

…. are the essential elements of our disruptive strategy.

First, we extract proteomic information from the sample to learn about the degradation context of the candidate protein. These include, the E3 ligase, associated factors, spatial and temporal parameters of target degradation, pathway crosstalk, and protein networks affecting proteostasis of the candidate protein.

Then we select the most viable solution. 

Rapid prototyping & iterating with a fail-fast, fail-forward mindset are our mantra for success!


 Our proprietary platforms, targeted assays, and knowledge systems for drug discovery

Target validation

The best clinical outcomes are expected by understanding the TPD candidate protein in its native environments 

Small molecule discovery

Our multiplexed assay screens a compound against any E3 ligases in the candidate cell type used for HTS

TPD solutions

Our peptides target most any E3 ligase substrate proteins and help with small molecule discovery for TPD.